Pharmaceutical industry in China

2020 China Pharmaceutical Distribution Market Analysis, with Key Players Profiles Including Nanjing Pharmaceutical Co., Ltd., China National Medicines Corp Ltd. and Huadong Medicine Co., Ltd.

Friday, May 29, 2020 - 10:45pm

DUBLIN, May 29, 2020 /PRNewswire/ -- The "China Pharmaceutical Distribution Industry Report, 2019-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, May 29, 2020 /PRNewswire/ -- The "China Pharmaceutical Distribution Industry Report, 2019-2026" report has been added to ResearchAndMarkets.com's offering.
  • The robust downstream demand spurs market growth and the market is forecast to be worth RMB4,225.7 billion by 2026.
  • Western medicine sales dominate pharmaceutical distribution in China, accounting for 72.2% in 2018 the sales in East China and Central South China seize larger shares up to 62.1% together in 2018.
  • Pharmaceutical distribution industry in China (development environment, status quo, market size/structure, competitive landscape, development trends, etc.)

Benchling Raises $50M Series D To Accelerate Biotech Revolution

Thursday, May 28, 2020 - 2:00pm

"Benchling has engineered an end-to-end, purpose-built software platform indispensable to life sciences companies leading the charge on global R&D.

Key Points: 
  • "Benchling has engineered an end-to-end, purpose-built software platform indispensable to life sciences companies leading the charge on global R&D.
  • Benchling doubled its customer base over the past year across industries ranging from pharmaceuticals and fuels to agriculture and food.
  • "Biotech will be a major market force in the coming decade," said Will Reed, general partner at Spark Capital.
  • As the world increasingly runs on biotech, biotech will run on Benchling."

Michael R. Dougherty Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.

Thursday, May 28, 2020 - 1:40pm

Prior to Celator, Mr. Dougherty served as Chief Executive Officer and a member of the board of directors of Kalidex Pharmaceuticals, Inc.

Key Points: 
  • Prior to Celator, Mr. Dougherty served as Chief Executive Officer and a member of the board of directors of Kalidex Pharmaceuticals, Inc.
  • Michaels broad executive, operational and governance experience in biotech is highly beneficial to our team at this critically important time.
  • BioSigs subsidiary ViralClear Pharmaceuticals, Inc., is seeking to develop a novel pharmaceutical to treat COVID-19.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133

Meitheal Pharmaceuticals Announces Launch of Enoxaparin Sodium Injection, USP in the United States

Thursday, May 28, 2020 - 1:00pm

Meitheal Pharmaceuticals, Inc. (Meitheal) , a fully integrated generic injectables company today announced the launch of Enoxaparin Sodium Injection, USP, the generic equivalent of Lovenox, in the United States market.

Key Points: 
  • Meitheal Pharmaceuticals, Inc. (Meitheal) , a fully integrated generic injectables company today announced the launch of Enoxaparin Sodium Injection, USP, the generic equivalent of Lovenox, in the United States market.
  • Meitheal licenses Enoxaparin Sodium Injection exclusively through its partnership with Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (NKF), its majority shareholder.
  • Enoxaparin had sales of approximately $570,878,217 in the United States, according to IQVIA data as of MAT (Moving Annual Total) March 2020.
  • Since 2017, Meitheal Pharmaceuticals has bridged critical gaps in the US healthcare market by supplying high quality, affordable generic injectables.

China Pharmaceutical Distribution Industry Report to 2026 - ResearchAndMarkets.com

Thursday, May 28, 2020 - 11:57am

The "China Pharmaceutical Distribution Industry Report, 2019-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Pharmaceutical Distribution Industry Report, 2019-2026" report has been added to ResearchAndMarkets.com's offering.
  • Western medicine sales dominate pharmaceutical distribution in China, accounting for 72.2% in 2018 the sales in East China and Central South China seize larger shares up to 62.1% together in 2018.
  • A competition pattern has been developed in the country where there are national pharmaceutical distributors represented by China National Pharmaceutical Group Corporation (Sinopharm), China Resources Pharmaceutical Commercial Group, Shanghai Pharmaceuticals and Jointown Pharmaceutical Group and the regional ones represented by NanJing Pharmaceutical, Guangzhou Pharmaceuticals, Chongqing Pharmaceutical, Huadong Medicine, Sichuan Kelun, Zhejiang Int'l, Realcan Pharmaceutical, Guangxi Liuzhou Pharmaceutical Co., Ltd. and Luyan Pharma Co., Ltd.
  • Pharmaceutical distribution industry in China (development environment, status quo, market size/structure, competitive landscape, development trends, etc.)

Supernus to Present at the Jefferies Virtual Health Care Conference

Wednesday, May 27, 2020 - 9:30pm

Investors interested in arranging a virtual meeting with the Company's management during this conference should contact the conference coordinator.

Key Points: 
  • Investors interested in arranging a virtual meeting with the Company's management during this conference should contact the conference coordinator.
  • A live webcast of the presentation can be accessed by visiting Events & Presentations in the Investor Relations section on the Company's website at www.supernus.com .
  • An archived replay of this webcast will be available for 60 days on the Company's website after the conference.
  • Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Allied Corp. Signs Sales, Distribution and Manufacturing Agreement With MGC Pharma

Wednesday, May 27, 2020 - 1:55pm

Under the terms of this agreement, MGC will manufacture Allieds products within their EU GMP (Good Manufacturing Practices) certified factory.

Key Points: 
  • Under the terms of this agreement, MGC will manufacture Allieds products within their EU GMP (Good Manufacturing Practices) certified factory.
  • This will enable Allied to have their pharma products produced under procedures and methods that meet the high quality standards of EU GMP.
  • In addition to this, through the MGC sales and distribution agreement, Allied will be able to sell their products following the completion of the PHASE I clinical trial.
  • We are excited to be working with MGC Pharma, a company with a proven track record in clinical research, manufacturing and sales of cannabis-based pharmaceuticals.

Milestone Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference

Wednesday, May 27, 2020 - 12:00pm

MONTREAL and CHARLOTTE, N.C., May 27, 2020 /PRNewswire/ --Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the Jefferies 2020 Healthcare Conference on Wednesday, June 3, 2020 at 8:30 AM ET.

Key Points: 
  • MONTREAL and CHARLOTTE, N.C., May 27, 2020 /PRNewswire/ --Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the Jefferies 2020 Healthcare Conference on Wednesday, June 3, 2020 at 8:30 AM ET.
  • The conference will be held in a virtual meeting format.
  • A live webcast of the presentation can be accessed in the News & Events section of Milestone's website at www.milestonepharma.com .
  • Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines.

Amunix Appoints Anne Keane as Senior Vice President of Regulatory and Quality

Wednesday, May 27, 2020 - 12:00pm

MOUNTAIN VIEW, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (Amunix), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers, today announced the appointment of Anne Keane as the Senior Vice President of Regulatory and Quality for Amunix.

Key Points: 
  • MOUNTAIN VIEW, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (Amunix), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers, today announced the appointment of Anne Keane as the Senior Vice President of Regulatory and Quality for Amunix.
  • We are excited to welcome Anne, a regulatory leader with significant experience across all phases of development, to Amunix, said Angie You, CEO of Amunix.
  • Anne Keane is an experienced regulatory leader with extensive experience across numerous therapeutic areas and phases of development.
  • While at Achaogen, Anne led the regulatory and clinical quality organizations through the development and approval of Zemdri, an important new antibiotic for gram negative infections.

DGAP-News: PharmaSGP Holding SE plans Initial Public Offering

Wednesday, May 27, 2020 - 8:01am

PharmaSGP offers a broad portfolio of leading chemical-free non-prescription pharmaceuticals sold over the counter ("OTC") and other healthcare products.

Key Points: 
  • PharmaSGP offers a broad portfolio of leading chemical-free non-prescription pharmaceuticals sold over the counter ("OTC") and other healthcare products.
  • In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RUBAXX(R) for rheumatic pain and RESTAXIL(R) for neuralgic pain.
  • The selling shareholders, who are serial entrepreneurs, are expected to sell pro-rata and will use the proceeds from the offering to fund capital intense projects outside PharmaSGP.
  • The offering is expected to consist of a public offering in Germany and international private placements.